Search
CN
About us
Our Company
Our Culture
Our History
Pipeline
Therapy
Product&Pipeline
Medicines
Health care
R&D
Complex Product and Platform
Innovative Medicines
Medical Devices
Technical Services(CDMO/CMO)
Partnering
Internationalization
R&D
One-stop service
Provide what you want
News
Press releases
Careers
Join us
Our Employees
Incentives
Opportunities
Investors
Investor contact
Contact us
CN
Home
About us
Our Company
Our Culture
Our History
Pipeline
Therapy
Product&Pipeline
Medicines
Health care
R&D
Complex Product and Platform
Innovative Medicines
Medical Devices
Technical Services(CDMO/CMO)
Partnering
Internationalization
R&D
One-stop service
Provide what you want
News
Press releases
Careers
Join us
Our Employees
Incentives
Opportunities
Investors
Investor contact
Contact us
Home
·
News
·
Press releases
·
Press releases
SCROLL DOWN
Press releases
Announcement of the receipt of the listing notice to
CF PharmTech, Inc.
Jul.25.2022
4155
Share
Back to list
Previous chapter
Good news from CF PharmTech | The first domestic blockbuster product for the treatment of allergic rhinitis - Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (ShuFeiMin ®) was approved
Next chapter
CF PharmTech has completed F round of 360 million yuan equity investment to support rapid development of domestic high-end inhalation products.
About us
Our Company
Our Culture
Our History
Pipeline
Therapy
Product&Pipeline
Medicines
Health care
R&D
Complex Product and Platform
Innovative Medicines
Medical Devices
Technical Services(CDMO/CMO)
Partnering
Internationalization
R&D
One-stop service
Provide what you want
News
Press releases
Careers
Join us
Our Employees
Incentives
Opportunities
Investors
Investor contact
Contact us
十大网投靠谱平台
|
LD.COM乐动官网(中国)有限公司
|
华亿体育(中国)股份有限公司
|
天博网页版【游戏】有限公司
|
博鱼app(中国)官方网站
|
华体app网页版(中国)有限公司
|
168体育官方网站丨中国有限公司
|
澳亚娱乐游戏(中国)官方有限公司
|
乐竞体育(中国)股份有限公司
|